Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy

Gastric and esopahgeal cancers account for the six most common causes of cancer death worldwide. Locally advanced resectable cancers have a 5-year life expectancy of 30%. Despite use of chemotherapy, median overall survival for stage IV cancer rarely exceeds 1 year. A subset of gastric cancers such...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Rutika, Shah, Anand, Almhanna, Khaldoun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177372/
https://www.ncbi.nlm.nih.gov/pubmed/30323626
http://dx.doi.org/10.2147/OTT.S152513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177372/
https://www.ncbi.nlm.nih.gov/pubmed/30323626
http://dx.doi.org/10.2147/OTT.S152513

Ejemplares similares